In vivo production of proteins
AssigneeModernaTX, Inc.
InventorsAntonin De Fougerolles, Justin Guild
Life of this patent
Estimating the term…
Abstract
The invention relates to compositions including polynucleotides encoding polypeptides which have been chemically modified by replacing the uridines with 1-methyl-pseudouridine to improve one or more of the stability and/or clearance in tissues, receptor uptake and/or kinetics, cellular access by the compositions, engagement with translational machinery, mRNA half-life, translation efficiency, immune evasion, protein production capacity, secretion efficiency, accessibility to circulation, protein half-life and/or modulation of a cell's status, function, and/or activity.
Claims18
A method of expressing a protein in a mammalian subject, the method comprising administering a pharmaceutical composition comprising a plurality of lipid nanoparticles encapsulating a polynucleotide, wherein the lipid nanoparticle comprises a biodegradable cationic lipid, a neutral lipid, cholesterol, and a PEGylated lipid and the plurality of lipid nanoparticles has a mean particle size of between 80 nm to 160 nm, and
- wherein the polynucleotide comprises:
- (a) an open reading frame encoding the protein consisting of nucleotides selected from 1-methyl-pseudouridine, cytidine, adenosine, and guanosine;
- (b) a 5′-UTR;
- (c) at least one 5′ cap structure;
- (d) a 3′-UTR;
- and
- (e) a 3′ tailing sequence of linked nucleosides.
Dependencies are inferred from the claim text.